July 1, 2017 Issue

The AARS online Hot Topics Newsletter is an exclusive AARS member benefit!

This is a semi-monthly compilation of peer-review literature and online updates in acne and rosacea covering industry press, new medical research and what patients and your peers are talking about in patient counseling tips.

Access Hot Topics Newsletter

You don't need to spend countless hours perusing your typical online sources when you have this! Stay informed today by becoming an AARS member and receiving the Hot Topics!

Industry News

  • BioPharmX Corp. recently presented results of its phase 2b study of BPX-01 for treating moderate-to-severe acne vulgaris showing that patients reported a positive experience with the topical minocycline gel at the Alabama Dermatology Society's Summer Symposium in Sandestin, Florida.
  • BioPharmX Corporation reported an update on BPX-01, its investigational topical drug for acne. The specialty pharmaceutical company presented comprehensive phase 2b clinical data during a recent "State of Acne" symposium showing that BPX-01 2% achieved its primary endpoint, reducing the number of inflammatory lesions in acne patients by 59%, compared with 44% in vehicle.

New Medical Research

  • Physicians should consider isotretinoin as a potential treatment for HS, as it may be beneficial in patients with mild and moderate disease and patients who are female, younger, weigh less, and have a personal history of acne.
  • A newly published study provides insight into the skin microbiota in acne and how it is modulated by systemic acne treatment. Reported for the first time is the effect of isotretinoin and lymecycline therapy on the skin microbiota.
  • The pinhole method with an Er:YAG laser could potentially be used as a safe and effective treatment for papular acne scars. Papular scars are one of the most difficult acne scars to treat yet good cosmetic results were achieved in this trial.
  • This study was conducted to compare the culture and polymerase chain reaction (PCR) methods for identifying P. acnes in lesions isolated from patients with acne. It was concluded that given the limitations in the identification of P. acnes using microbial culture, PCR is proposed as a better method with a higher efficiency.
  • Rosacea-prone individuals can benefit from well tolerated Daylong Extreme SPF 50+ lotion on their faces, producing objective and subjective improvements in skin status and symptoms.
  • Results from this cross-sectional study suggest a relationship between dietary carbohydrate, including GL, and acne. Future research is necessary to determine the effect of medical nutrition therapy on biological factors associated with acne and acne severity.

Clinical Reviews

  • Acne fulminans (AF) is an uncommon and incompletely understood severe variant of inflammatory acne. These guidelines better characterize AF providing a more complete understanding and provide health care practitioners approaches to the classification, treatment, and prevention of AF and its variants.
  • Use of topical and systemic antibiotics for acne is associated with formation of resistance in Propionibacterium acnes and other bacteria, with clinical consequences. Guidelines recommend resistance reduction strategies including avoidance of antibiotic monotherapy, combination treatment with topical modalities, and limiting the duration of oral antibiotic use.
  • The majority of adverse events associated with current topical drugs for rosacea resulted in treatment switch or discontinuation. Drugs with a different mechanism of action or new formulations of existing drugs may provide additional treatment options for patients and may lead to improved adherence and better symptom control.
  • A search for phase 1 and 2 acne treatment trials in the US National Institutes of Health database of clinical trials and the European Medicines Agency database found that topical agents may act via sebosuppressive effects, antimicrobial properties or anti-inflammatory actions.
  • To achieve a complete remission of cutaneous and ocular rosacea, a long-term anti-inflammatory treatment of at least six months is necessary. The remission and relapse rates after successful treatment seem to be lower than in adults as all nine patients treated with erythromycin achieved a complete remission and did not show any relapse.
  • A study aimed to establish standardized overall and group-specific prevalence estimates for HS and determined that Hidradenitis suppurativa is an uncommon, but not rare, disease in the United States that disproportionately affects female patients, young adults, and African American and biracial patients.

Patient Counseling / Communication

  • Recent study reviewed current evidence that links air pollution to worsening of acne symptoms and identified the need for further epidemiological and clinical research. Additionaly, the authors suggest that people with acne should protect the natural barrier function of their skin with emollients and ultraviolet (UV)A/UVB protection.
  • Managing Patient Concerns regarding Isotretinoin for Acne by following the tips described in this article such as becoming a well informed prescribing physician, enrolling in iPLEDGE, and identifying other physicians in your area for referrals.